KORU Medical Systems, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- KORU Medical Systems, Inc. (NASDAQ: KRMD) develops, manufactures and commercializes innovative subcutaneous infusion solutions for home and specialty infusion therapy, targeting patients with chronic illnesses including primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD) and paroxysmal nocturnal hemoglobinuria (PNH). The company offers the FREEDOM Integrated Infusion System comprising the FREEDOM60 and FreedomEdge syringe drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and related accessories; these mechanical, ambulatory devices enable precise, large-volume subcutaneous drug delivery such as immunoglobulin therapies in ambulatory and home settings. KORU Medical Systems operates in the United States and internationally through distributors, direct sales and pharmaceutical partnerships, with approximately 80 employees led by President and CEO Linda Tharby. Founded in 1980 and formerly known as Repro Med Systems, Inc., the company is headquartered at 100 Corporate Drive, Mahwah, New Jersey. Recent developments include a November 2025 development agreement with a global pharmaceutical company for next-generation subcutaneous immunoglobulin (SCIg) infusion systems supporting commercial drugs and clinical programs; two additional Pharma Services and Clinical Trials collaborations announced in early 2025 expanding patient reach; 27% year-over-year Q3 2025 revenue growth to $10.4 million driven by core SCIg business; raised 2025 revenue guidance; and four novel therapies collaborations entered in 2024 alongside positive adjusted EBITDA and cash flow generation.
KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress
KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
KORU Medical Systems Announces First Quarter 2026 Results
KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026
KORU Medical Systems, Inc. $KRMD Shares Bought by Acuitas Investments LLC
KORU Medical Secures EU MDR Certification for Freedom60 Infusion Pump
KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript
KORU Medical Systems, Inc. (KRMD) Reports Q4 Loss, Beats Revenue Estimates
KORU Medical Systems Announces CEO Transition
KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance
Brokerages Set KORU Medical Systems, Inc. (NASDAQ:KRMD) Price Target at $6.13
Down 18.1% in 4 Weeks, Here's Why KORU Medical Systems, Inc. (KRMD) Looks Ripe for a Turnaround
Analyzing KORU Medical Systems (NASDAQ:KRMD) and Outset Medical (NASDAQ:OM)
KORU Medical Systems, Inc. (NASDAQ:KRMD) Receives $6.13 Average PT from Analysts
KORU Medical Systems, Inc. (KRMD) Soars 5.6%: Is Further Upside Left in the Stock?
Acuitas Investments LLC Reduces Position in KORU Medical Systems, Inc. $KRMD
KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System
All You Need to Know About KORU Medical Systems, Inc. (KRMD) Rating Upgrade to Buy